Oral News and Research

RSS

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.

24 Dec 2015

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center.

24 Dec 2015

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease.

24 Dec 2015

Bioactive glass may help prolong life of composite tooth fillings

A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.

23 Dec 2015

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding.

23 Dec 2015

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

The American College of Cardiology has launched a new STS/ACC TAVR In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

Periodontal disease may increase breast cancer risk

Postmenopausal women with periodontal disease were more likely to develop breast cancer than women who did not have the chronic inflammatory disease. A history of smoking significantly affected the women's risk.

21 Dec 2015

Australian researchers develop new technique to combat chronic bacterial infections in hospitals

One of the scourges of infections in hospitals – biofilms formed by bacteria that stick to each other on living tissue and medical instruments, making them harder to remove – can be tricked into dispersing with the targeted application of nanoparticles and heat, researchers have found.

21 Dec 2015

Poor outlook for ICH associated with novel oral anticoagulants

Haematoma expansion, disability and death are common among patients who have intracerebral haemorrhage while taking novel oral anticoagulants, a study in JAMA Neurology shows.

18 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Study examines effect of nonoperative treatment for appendicitis

It is too early to change the standard treatment of appendicitis in U.S. adults to initial antibiotic therapy only, rather than surgical removal of the appendix, or appendectomy, authors of a new systematic review study conclude.

18 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Oral News and Research

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Selexipag holds promise for treatment of pulmonary hypertension

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

IASLC lauds FDA approval of alectinib for lung cancer treatment

Bioactive glass may help prolong life of composite tooth fillings

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

SciClone plans to pursue development of SGX942 in the Greater China market

Periodontal disease may increase breast cancer risk

Australian researchers develop new technique to combat chronic bacterial infections in hospitals

Poor outlook for ICH associated with novel oral anticoagulants

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Study examines effect of nonoperative treatment for appendicitis

Novel strategies on the way for difficult-to-treat head and neck cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News